239 related articles for article (PubMed ID: 27913522)
1. Role of stem cell transplant and maintenance therapy in plasma cell disorders.
McCarthy PL; Holstein SA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):504-511. PubMed ID: 27913522
[TBL] [Abstract][Full Text] [Related]
2. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
3. Stem Cell Transplantation in Multiple Myeloma.
Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
5. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
Gay F; Cavallo F; Palumbo A
Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394
[TBL] [Abstract][Full Text] [Related]
6. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients.
Gentile M; Vigna E; Recchia AG; Morabito L; Martino M; Morabito F
Expert Opin Pharmacother; 2014 Jul; 15(10):1315-20. PubMed ID: 24819321
[TBL] [Abstract][Full Text] [Related]
7. Role of consolidation therapy in transplant eligible multiple myeloma patients.
Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
9. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Maybury B; Cook G; Pratt G; Yong K; Ramasamy K
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1926-1937. PubMed ID: 27288955
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: Role of autologous transplantation.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Kastritis E; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2020 Jan; 82():101929. PubMed ID: 31770695
[TBL] [Abstract][Full Text] [Related]
11. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.
Cornell RF; Kassim AA
Bone Marrow Transplant; 2016 Apr; 51(4):479-91. PubMed ID: 26726946
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
13. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
14. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
Richardson PG; Laubach JP; Munshi NC; Anderson KC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):255-61. PubMed ID: 25696864
[TBL] [Abstract][Full Text] [Related]
15. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.
Nathwani N; Larsen JT; Kapoor P
Curr Hematol Malig Rep; 2016 Apr; 11(2):127-36. PubMed ID: 26893062
[TBL] [Abstract][Full Text] [Related]
16. Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Mohty M; Richardson PG; McCarthy PL; Attal M
Bone Marrow Transplant; 2015 Aug; 50(8):1024-9. PubMed ID: 25893452
[TBL] [Abstract][Full Text] [Related]
17. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
18. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C
Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Malard F; Harousseau JL; Mohty M
Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
[TBL] [Abstract][Full Text] [Related]
20. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
